EAU 2013 - Programme Book - YouMed

Monday, 18 March - EAU Programme
Abstract Session
15.45 - 17.15 Prostate cancer biomarkers and outcome prediction
Amber Hall 1-2 - Level S2
Poster Session 85
Chairs: B. Djavan, Vienna (AT)
G.N. Thalmann, Berne (CH)
Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes
in length, followed by 2 minutes for discussion. Extended presentations (*) are 4 minutes in length, followed
by 2 minutes for discussion.
* 1039 Genetic testing in identification of BPH patients developing later prostate cancer
L. Saaristo, T. Wahlfors, J. Schleutker, H. Lilja, T. Tammela, M. Matikainen (Tampere, Turku, Helsinki,
Finland)
1040 Expression of candidate susceptibility genes in the development and progression of prostate cancer
C. Debiais-Delpech, J. Godet, N. Pedretti, J. Irani, X. Cathelineau, G. Fromont (Poitiers, Gençay, Paris, France)
1041 Neurofuzzy system for prostate cancer risk evaluation
L. Benecchi, F. Bocchi, M. Potenzoni, F. Russo, L. Perucchini, M. Quarta, M. Tonghini, P. Bocchi, C. Del Boca
(Cremona, Parma, Italy)
1042 Detection of prostate cancer associated α2,3 sialyated free PSA in serum is more higher specificity than
conventional PSA test
T. Yoneyama, Y. Tobisawa, K. Mori, S. Hatakeyama, H. Yamamoto, T. Okamoto, A. Okamoto, F. Ishimura,
T. Yoneyama, T. Koie, N. Kamimura, C. Ohyama (Hirosaki, Japan)
1043 Association of blood level omega-3 fatty acids with risk of prostate cancer: A meta-analysis
M. Chua, M.C. Sio, M. Sorongon, M.J. Morales (Quezon City, Philippines)
1044 Frequency and prognostic significance of TMPRSS2-ERG gene fusion in prostate cancers with positive
lymph nodes
A. Fleischmann, I. Zlobec, T. Visakorpi, G.N. Thalmann (Berne, Switzerland; Tampere, Finland)
* 1045 Urinary PCA3 and TMPRSS2:ERG help predict biopsy outcome prior to initial prostate biopsy using a risk
group analysis
J.R. Day, L.A. Jones, S.E. Meyer, P.N. Hodge, J. Aussie, D.R. Saltzstein, J.C. Groskopf (San Diego, San Antonio,
United States of America)
1046 A new medical device for in vivo isolation of circulating tumor cells in prostate cancer patients
G. Theil, M.R. Hoda, K. Fischer, K. Haubold, T. Krahn, N.G. Morgenthaler, K. Lücke, P. Fornara (Halle/Saale,
Potsdam, Berlin, Germany)
1047 Expression of epithelial-mesenchymal transition markers in localized prostate cancer: Impact on
clinicopathological outcomes in patients undergoing radical prostatectomy
H. Miyake, H. Behnsawy, M. Fujisawa (Kobe, Japan)
1048 CSAG4 and NOL4 are novel biomarkers to indicate aggressiveness of prostate cancer
S. Takahashi, T. Shiraishi, B.J. Trock, P. Kulkarni, R. Getzenberg, T. Tominaga, Y. Homma (Tokyo, Japan;
Maryland, United States of America)
EAU Milan 2013
305
Monday